News in brief

BioDuro teams up with API developer Porton

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/daizuoxin)
(Image: iStock/daizuoxin)

Related tags: Pharmacology

The San Diego-CA-based contract research, development, and manufacturing organization (CDMO), BioDuro, has announced a cooperation agreement with Porton Pharma Solutions.

Previously Porton Fine Chemicals, the newly renamed company operates three process technology centers and three manufacturing sites in China.

Under the cooperation agreement, BioDuro will promote and market Porton's custom active pharmaceutical ingredient (API) and cGMP manufacturing services.

In turn, Porton will incorporate BioDuro's technologies and resources in drug discovery, as well as its formulations development and clinical trial materials (CTMs) manufacturing capabilities, into its solutions suite.

Cyrus K. Mirsaidi, BioDuro president and CEO, said the partnership expands the company’s reach to provide fully integrated API and drug product development and manufacturing solutions.

"Porton's global footprint and proven track record with many of the world's leading pharmaceutical companies will provide substantiated channels for timely and reliable delivery of high value therapeutics, using innovative and cost effective manufacturing routes, backed by high-quality assets in Asia and North America​," he said in a press release.

Related news

Show more

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us


View more